Certified by Founder
Lodge
smartbax
start up
Germany
- München
- 24/05/2023
- Seed
- $1,291,000
smartbax develops novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms. With the first-in-class compounds, the company targets the multi-drug resistant pathogens methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
- Industry Biotechnology Research
- Website https://www.smartbax.de/
- LinkedIn https://www.linkedin.com/company/smartbax-gmbh/